Board MeetingMay 22, 2026, 09:02 AM
BioAge Labs to Participate in Jefferies & Goldman Sachs Healthcare Conferences
AI Summary
BioAge Labs, Inc. announced its participation in two upcoming investor conferences: the Jefferies Global Healthcare Conference in New York and the Goldman Sachs Global Healthcare Conference in Miami Beach. CFO Dov Goldstein and Chief Strategy Officer BJ Sullivan will represent the company, participating in fireside chats and one-on-one meetings. The company, a clinical-stage biotechnology firm, is developing therapeutic candidates for metabolic diseases, with its lead candidate BGE-102 targeting cardiovascular risk and retinal diseases.
Key Highlights
- BioAge Labs CFO Dov Goldstein and CSO BJ Sullivan to participate in Jefferies Global Healthcare Conference on June 4, 2026.
- BioAge Labs CFO Dov Goldstein and CSO BJ Sullivan to participate in Goldman Sachs Global Healthcare Conference on June 8, 2025.
- Company's lead product candidate, BGE-102, is an NLRP3 inhibitor for cardiovascular risk and retinal diseases.
- Phase 2 cardiovascular risk proof-of-concept data for BGE-102 anticipated by end of 2026.
- Phase 1b/2a diabetic macular edema proof-of-concept data for BGE-102 anticipated in mid-2027.
- Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity.
Price Impact
More from BIOA